PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Urological literature review: November 2004 ? October 2005. Part II
Article published in Urologia Polska 2006/59/2.

authors

Andrzej Borkowski, Tomasz Borkowski
Klinika Urologii Akademii Medycznej w Warszawie

references

  1. Evans CP, Fleshner N, Fitzpatrick JM et al: An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU International 2005, 95, 743-749.
  2. Han M, Brannigan RE, Antenor JAV et al: Association of hemospermia with prostate cancer. J Urol 2004, 172, 2189-2192.
  3. Kravchick S, Peled R, Ben-Dor D et al: Comparison of different local anesthesia techniquesduring Trus-guided biopsies: a prospective pilot study. Urology 2005, 65, 109-113.
  4. Das D, Dasgupta P, Chandra A: Alpha-acylmethyl co-enzyme A racemase: a tumour maker for the 21st century. BJU International 2005, 95, 3-4.
  5. Imamoto T, Suzuki H, Fukasawa S et al: Pretreatment serum testosterone level as a predictive factor of pathological stage in localised prostate patients treated with radical prostatectomy. Eur Urol 2005, 47, 308-132.
  6. D?Amico AV, Chen M-H, Roehl KA et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351, 125-135.
  7. Eisenberger M, Partin A: Progress toward identifying aggressive prostate cancer. N Engl J Med 2004, 351, 180-181.
  8. Teixeira MR, Ribeiro FR, Eknaes M et al: Genomic analysis of prostate cancer specimens obtained via ultrasound-guided needle biopsy may be use in preoperative decision-making. Cancer 2004, 101, 1786-1793.
  9. Yu YP, Landsittel D, Jing L et al: Gene expression alterations in prostate cancer predicting tumor aggression and predicting development of malignancy. J Clin Oncol 2004, 22, 2790-2799.
  10. Kirby RS, Fitzpatrick JM: How should we advise patients about the chemoprevention of prostate cancer. BJU International 2005, 96, 231-236.
  11. Klotz L: Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005, 47, 16-21.
  12. Hardie C, Parker Ch, Norman A et al: Early outcomes of active surveillance for localized prostate cancer. BJU International 2005, 95, 956-960.
  13. Khan MA, Mangold LA, Epstein JI et al: Impact or surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 2004, 172, 1835-1839.
  14. Moore CM, Hoh IM, Bown SG et al: Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confied prostate cancer? BJU International 2005, 96, 754-758.
  15. Jeschke S, Nambirajan T, Leeb K et al: Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005, 173, 1943-1946.
  16. Richman M, McLaughlin S, Matgarden S et al: Initial incision of lateral pelvic fascia and early ligation of vascular pedicles during radical prostatectomy: potential to reduce positive margin rates. BJU International 2005, 95, 40-45.
  17. Takenaka A, Hara R, Soga H et al: A novel technique for approaching the endopelvic fascia in retropubic radical prostatectomy, based on an anatomical study of fixed and fresh cadavers. BJU International 2005, 95, 766-771.
  18. Ward JF, Sebo TJ, Blute ML et al: Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005, 173, 1156-1160.
  19. Jani AB, Kao J: Postprostatectomy adjuvant versus salvage radiotherapy. Cancer 2005, 103, 1833-1842.
  20. Pazona JF, Han M Hawkins SA et al: Salvage radiation therapy for prostate specific antygen progression following radical prostatectomy: 10 year outcome estimates. J Urol 2005, 174, 1282-1286.
  21. Copp H, Bissonette EC, Theodorescu D et al: Tumor control outcomes of patients reated with trimodality therapy for locally advanced prostate cancer. Urology 2005, 65, 1146-1151.
  22. Satyha JR, Davis IA, Julian JA et al: Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23, 1192-1199.
  23. Gulley JL, Figg WD, Steinberg SM et al: A prospective analysis of a time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005, 173, 1567-1571.
  24. Thurairaja R, Persad R, Peters J et al: The ?flare? phenomenon: should we be concerned? BJU International 2005, 95, 4-6.
  25. Langenstroer P, Kramer B, Cutting B et al: Paraenteral medroxyprogesterone for the management of hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 2005, 174, 642-645.
  26. Krupski TL, Smith MR, Lee WCh et al: Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004, 101, 541-548.
  27. Magno C, Anastasi G, Morabito M et al: Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with Neridronate. Eur Urol 2005, 47, 575-581.
  28. Agarwal MM, Khandewal N, Mandal AK et al: Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 2005, 103, 2042-2052.
  29. Ockrim JL, Lalani EM, Banks LM et al: Transdermal estradiol improves bone density when used as a single agent therapy for prostate cancer. J Urol 2004, 172, 2203-2207.
  30. Bland LB, Garzotto M, deLoughery TG et al: Phase II study of transdermal Estradiol in androgen independent prostate cancer. Cancer 2005, 15, 717-723.
  31. Tannock IF, de Wit R, Berry WR et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351, 1502-1512.
  32. Petrylak DP, Tangen CM, Maha PH et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351, 1513-1520.
  33. Berry WR: The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology 2005, 65 (suppl 6A), 2-7.
  34. Clarke NW, Wylie JP: Chemotherapy in hormone refractory prostate cancer: where do we stand? Eur Urol 2004, 46, 709-711.
  35. Kibel AS: An interdisciplinary approach to treating prostate cancer. Urology 2005, 65 (suppl 6A), 13-18.
  36. Goodin S, Medina P, Capana T et al: Efect of docetaxel in patients with hormone-dependent prostate-specific progression after local therapy for prostate cancer. J Clin Oncol 2005, 23, 3352-3357.
  37. Carducci MA: What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer. J Clin Oncol 2005, 23, 3304-3307.
  38. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J M 2004, 351, 1488-1490.
  39. Small EJ: Monoclonal antibody therapy for prostate cancer: finally a reality. J Clin Oncol 2004, 22, 2515-2516.
  40. Canto EI, Singh H, Shariat SF et al: Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004, 63, 905-911.
  41. Slawin KM, Kattan MW: BPH serum markers and nomograms for selecting candidates for medical therapy. AUA News 2005, 10, nr april/may, str 5-6.
  42. McNeill SA, Hargreave TB, Roehrborn CG et al: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005, 65, 83-90.
  43. Lucas MG, Stephenson TP, Nargund V: Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International 2005, 95, 354-357.
  44. Millan-Rodriguez F, Izquierdo-Latore M, Montlleo-Gonzales M et al: Treatment of bladder stones without associated prostate surgery: results of a prospective study. Urology 2005, 66, 505-509.
  45. Smith ChP, Radziszewski P, Borkowski A et al: Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004, 64, 871-875.
  46. Anderson RU, Wise D, Sawyer T et al: Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005, 174, 155-160.
  47. Oyama IA, Rejba A, Lukban JC et al: Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004, 64, 862-865.
  48. Thom DH, Nygaard IE, Calhoun EA: Urologic diseases in America project: urinary incontinence in women-national trends in hospitalization, office visits, treatment and economic impact. J Urol 2005, 173, 1295-1301.
  49. Spinoza JP, Dubuis PY, Riederer B: Chirurgie de l?incontinence a l?effort feminine par voie transobturatrice: dehors-dedans ou dedans-dehors? Etude anatomique comparative. Progres en Urologie 2005, 15, 700-706.
  50. Flynn MK, Webster GD, Amundsen CL: The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004, 172, 2316-2320.
  51. Hussain M, Greenwell TJ, Venn SN et al: The current role of the artificial urinary sphincter for the treatment of urinary incontinence. J Urol 2005, 174, 418-424.
  52. Stern JA, Clemens JQ, Tiplitsky SI et al: Long-term results of the bulbourethral sling procedure. J Urol 2005, 173, 1654-1656.
  53. Fassi-Fehri H, Cherasse A, Badet L al: Traitement de l?incontinence post-operatoire de l?homme par la prothese INVANCE: resultats preliminaires. Progres en Urologie 2004, 14, 1171-1176.
  54. Hubner WA, Schlarp OM: Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. BJU International 2004, 96, 587-594.
  55. Bauer W, Karik M, Schramek P: The self-anchoring transobturatormale sling to treat stress urinary incontinence in men: a new sling, a surgical approach and anatomical findings in a cadaveric study. BJU International 2005, 95, 1364-1366.
  56. Jones JS, Vasavada SP, Abdelmalak JB et al: Sling may hasten return of continence after radical prostatectomy. Urology 2005, 65, 1163-1167.
  57. Karlovsky ME, Tharke AA, Rastinehad A et al: Biomaterials for pelvic floor reconstruction. Urology 2005, 66, 469-475.
  58. Wespes ME, Rammal A, Garbar Ch: Sildenafil non-responders: haemodynamic and morphometric study. Eur Urol 2005, 48, 136-139.
  59. Shioshvili TJ, Kakonashvili AP: The surgical treatment of Peyronie?s disease: replacement of plaque by free autograft of bucal mucosa. Eur Urol 2005, 48, 129-135.
  60. Gettman MT, Blute ML, Chow GK et al: Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with daVinci robotic system. Urology 2004, 64, 914-918.
  61. Zhang X, Ma X, Li H-Z et al: Retroperineoscopic subcapsular nephrectomy for infective nonfunctioning kidney with dense perinephric adhesions. BJU International 2004, 94 1329-1331.
  62. Rubinstein M, Finelli A, Moinzadeh A et al: Outpatient laparoscopic pyeloplasty. Urology 2005, 66, 41-44.
  63. Lusuardi M, Lodde M, Pycha A: Cutaneous ureterostomy. BJU International 2005, 96, 1149-1159.
  64. Delivelitos C, Papatsoris A, Chrisofos M et al: Urinary dversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology 2005, 66, 299-304.
  65. Kishore TA, Bhat S, John RP: Colour Doppler ultrasonographic location of the bulbourethral artery, and its impact on surgical outcome. BJU International 2005, 96, 624-628.
  66. Pareek G, Armenakas NA, Panagopoulos G et al: Extracorporeal shock wale lithotripsy success based on body mass index and Hounsfield units. Urology 2005, 65, 33-36.
  67. Yilmaz E, Batislam E, Basar MM et al: The comparison and efficacy of 3 different alfa1 adrenergic blockers for distal ureteral stone. J Urol 2005, 173, 2010-2012.
  68. Gravina GL, Costa AM, Ronchi P et al: Tamsulosin treatment increases clinical sukces rate of single extracorporeal shock wave lithotripsy of renal stones. Urology 2005, 66, 24-28.
  69. Knudsen BE, Chew BH, Denstedt JD: Drug-eluting biomaterials in urology: the time is ripe. BJU International 2005, 96, 726-727.
  70. Kirby R, Gould D: Testosterone replacement therapy in hypogonadal men and prostate cancer risk. BJU International 2005, 96, 471-476.

correspondence

Andrzej Borkowski
Klinika Urologii AM
ul. Lindleya 4
02-500 Warszawa
tel. (022) 502 17 23
urolwa@warman.com.pl